Safinamide: a novel anti-Parkinsonian drug with multiple actions

Author： Borgohain Rupam   Kandadai Rukmini Mridula  

Publisher： Future Medicine

ISSN： 1758-2024

Source： Neurodegenerative Disease Management, Vol.3, Iss.3, 2013-06, pp. : 231-240

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Novel Anti-Parkinsonian Agent, Zonisamide, Attenuates MPTP-Induced Neurotoxicity in Mice

By Yano Ryohei  

Journal of Molecular Neuroscience, Vol. 39, Iss. 1-2, 2009-09 ,pp. : 211-219

Humana Press, Inc

Access to resources Recommend Favorite

A Novel Anti-Parkinsonian Agent, Zonisamide, Attenuates MPTP-Induced Neurotoxicity in Mice

By Yano Ryohei  

Journal of Molecular Neuroscience, Vol. 39, Iss. 1-2, 2009-09 ,pp. : 320-320

Humana Press, Inc

Access to resources Recommend Favorite

Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis

By Morsali Damineh  

Brain, Vol. 136, Iss. 4, 2013-04 ,pp. : 1067-1082

Oxford University Press

Access to resources Recommend Favorite

Antiparkinsonian Actions of Ifenprodil in the MPTP-Lesioned Marmoset Model of Parkinson's Disease

By Nash J.E.   Fox S.H.   Henry B.   Hill M.P.   Peggs D.   McGuire S.   Maneuf Y.   Hille C.   Brotchie J.M.   Crossman A.R.  

Experimental Neurology, Vol. 165, Iss. 1, 2000-09 ,pp. : 136-142

Elsevier

Access to resources Recommend Favorite

Antiparkinsonian Actions of Blockade of NR2B-Containing NMDA Receptors in the Reserpine-Treated Rat

By Nash J.E.   Hill M.P.   Brotchie J.M.  

Experimental Neurology, Vol. 155, Iss. 1, 1999-01 ,pp. : 42-48

Elsevier

Access to resources Recommend Favorite